SINGAPORE, 14 APRIL 2022: Us2.ai, the Singapore-based medtech developers of FDA- cleared AI software that, for the first time ever, fully automates a complete echocardiography (heart ultrasound) report, today announced...
Sequenom licenses worldwide rights to develop age-related macular degeneration diagnostic test
SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- Sequenom, Inc. (NASDAQ: SQNM), today announced an exclusive worldwide licensing agreement with Optherion, Inc. Under the agreement, Sequenom’s CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age- related macular degeneration (AMD).